Cormorant Asset Management’s Astria Therapeutics ATXS Stock Holding History

Cormorant Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,300,000	Closed	-$18.3M	–	52
2024 Q1	$18.3M	Buy	+1,300,000	New	+$16.2M	0.8%	35
2023 Q3	–	Sell	-1,000,000	Closed	-$8.33M	–	53
2023 Q2	$8.33M	Hold	1,000,000	–	–	0.47%	43
2023 Q1	$13.3M	Sell	1,000,000 -650,000	-39%	-$8.79M	0.88%	32
2022 Q4	$24.6M	Buy	1,650,000 +450,000	+38%	+$4.64M	1.64%	21
2022 Q3	$10.8M	Buy	1,200,000 +900,000	+300%	+$6.03M	0.76%	39
2022 Q2	$900K	Hold	300,000	–	–	0.07%	75
2022 Q1	$2.01M	Sell	300,000 -252,903	-46%	-$1.51M	0.15%	66
2021 Q4	$2.98M	Hold	552,903	–	–	0.18%	66
2021 Q3	$4.89M	Sell	552,903 -38,764	-7%	-$371K	0.2%	69
2021 Q2	$7.49M	Buy	+591,667	New	+$7.68M	0.25%	70
2017 Q1	–	Sell	-13,333	Closed	-$2.89M	–	76
2016 Q4	$2.89M	Hold	13,333	–	–	0.39%	52
2016 Q3	$4.93M	Buy	+13,333	New	+$3.51M	0.54%	51

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Cormorant Asset Management's ATXS Position: Q2 2024 in Review

Cormorant Asset Management sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 1,300,000 shares — an estimated $18.3M sold.

Cormorant Asset Management first reported a position in ATXS in Q3 2016 and held it in 12 quarters. The position peaked at $24.6M in Q4 2022. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

Cormorant Asset Management reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
Cormorant Asset Management sold 1,300,000 Astria Therapeutics shares in Q2 2024, an estimated $18.3M.
Cormorant Asset Management first reported a position in Astria Therapeutics in Q3 2016 and held it in 12 quarters.
Cormorant Asset Management's Astria Therapeutics position peaked at $24.6M in Q4 2022.
100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.